Skip to main content
Clinical Trials/ACTRN12609001059257
ACTRN12609001059257RecruitingPhase 2

Gonadotropin-releasing hormone analogue cotreatment does not preserve ovarian function in young women receiving cyclophosphamide-based chemotherapy: a prospective, multicenter, randomized trial

Ass. Prof. Dr. Eman Elgindy0 sites100 target enrollmentStarted: December 10, 2009Last updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Recruiting
Sponsor
Enrollment
100

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Randomised controlled trial
Primary Purpose
Prevention
Masking
Open (masking not used)

Eligibility Criteria

Ages
18 Years to 40 Years (—)
Sex
Female

Inclusion Criteria

  • Women between 18 and 40 years old receiving cyclophosphamide-based chemotherapy for treatment of cancer with presence of both ovaries and absence of ovarian tumours or cysts over 40 mm in diameter demonstrated by transvaginal ultrasound

Exclusion Criteria

  • Advanced stage disease or evidence of metastases; Cancer of the ovaries, uterus, or fallopian tubes; Women who previously received chemotherapy or abdominal/pelvic radiation or are planned to receive abdomino-pelvic radiation; Patients taking hormone therapy biologic therapy or corticosteroids; Women who are pregnant or nursing.

Investigators

Sponsor
Ass. Prof. Dr. Eman Elgindy

Similar Trials